


**Product Name** : Sovleplenib  
**Cat. No.** : PC-73445  
**CAS No.** : 1415792-84-5  
**Molecular Formula** : C<sub>24</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>S  
**Molecular Weight** : 482.603  
**Target** : Syk  
**Solubility** : 10 mM in DMSO



## Biological Activity

Sovleplenib (HMPL-523) is a highly potent, selective, orally available **SYK** inhibitor with IC<sub>50</sub> of 25 nM, demonstrates anti-tumor activity in B cell lymphomas.

HMPL-523 blocked phosphorylation of BLNK, downstream protein of Syk, in human mantle cell line REC-1 and human plasma cell line ARH-7777 with IC<sub>50</sub> of 0.105 μM and 0.173 μM, respectively.

HMPL-523 also inhibited cell viability of Ba/F3 Tel-Syk with IC<sub>50</sub> of 0.033 μM.

HMPL-523 potently inhibited cell viability in a panel of B -cell lymphoma cell lines with SYK/BCR deregulation with IC<sub>50</sub> of 0.4 to 2 μM.

HMPL-523 increased the apoptotic rate of REC-1 cells, showed the synergistic activities on killing human DLBCL in combination with BTK inhibitor, PI3Kδ inhibitors and Bcl2 family inhibitor.

HMPL-523 (100 mg/kg, p.o.) showed potent anti-tumor activity in B cell lymphoma REC-1, demonstrated anti-tumor activity in Syk dependent xenograft models.

## References

Na Yang, et al. *Blood* (2016) 128 (22): 3970.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com